Business

Diaceutics PLC – Directorate Changes

Diaceutics PLC – Directorate Changes.

articleDiaceutics PlcSeptember 21, 20235/company/diaceutics-plc/news/diaceutics-plc-directorate-changes
Diaceutics PLC – Directorate Changes

About this update from Diaceutics Plc

[{"type":"text","content":"\n\nDiaceutics PLC - Directorate Changes\n \nGraham Paterson appointed as an independent Non-Executive Director\n \nCharles Hindson retiring as a Non-Executive Director\n \nBelfast and London, 21 September 2023 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, today announces the appointment of Graham Paterson as an independent Non-Executive Director of Diaceutics PLC effective 1 October 2023. The Company also announces the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023.\n \nGraham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc. He has held senior executive roles in a number of companies including TopQ Software Ltd and SL Capital Partners.\n \nGraham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC.\n \nDeborah Davis, Diaceutics' Non-Executive Chair, commented: \"I would like to thank Charles for his hard work, dedication and much valued counsel during the past four years and wish him well in his future endeavours.\n \nI warmly welcome Graham to the board of Diaceutics, his extensive leadership and board experience will contribute significantly to our work and support our growth as we become the primary commercialisation partner for pharma and biotech companies launching precision medicines.\"\n \nInformation required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:\nThe following information is disclosed in relation to Graham Douglas Paterson, aged 52:\n\n\n\nCurrent Directorships\n\n\nPast Directorships (previous 5 years)\n\n\n\n\nBaillie Gifford US Growth Trust Plc\n \nInvesco Perpetual UK Smaller Companies Investment Trust Plc\n \nMobeus Income and Growth 4 VCT Plc\n \nDatactics Ltd\n \nSubstantive Research Ltd\n \nThe Wemy...

More updates from Diaceutics Plc